Disclaimer

Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) Clinical research trials and Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec). Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) clinical trial. Human subjects often get the best healthcare possible for their Phase II trial of decitabine in patients with chronic myelogenous leukemia accelerated phase who are refractory to imatinib mesylate (Gleevec) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.